Global (United States, European Union and China) Oral Proteins and Peptides

Oral Proteins and Peptides Comprehensive Study by Type (Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide), Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders), Distribution Channel (Hopsitals, Pharmaceuticals), End Use (Hospitals, Physicians’ offices, Commercial laboratories, Health care centers) Players and Region - Global Market Outlook to 2026

Oral Proteins and Peptides Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Proteins and Peptides are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases, which can be administered orally are known as oral peptide and protein-based drugs. The demand for oral peptide and protein-based therapeutics has increased significantly, owing to increase in prevalence of chronic diseases, rise in patient preference for oral drugs, and enhanced patient compliance. Furthermore, surge in elderly population along with improvement in healthcare settings boost the market.

Market Drivers
  • Increase in prevalence of chronic diseases,
  • Rise in patient preference for oral drugs and enhanced patient compliance
  • Surge in elderly population

Market Trend
  • Improvement in healthcare settings

Restraints
  • Hgh costs associated with oral peptides and proteins

Opportunities
Increase in R&D by pharmaceutical companies and and Surge in the purchasing power of emerging economies

Players Covered in the Study are:
Allergan (Ireland), AstraZeneca (United Kingdom), Biocon (India), Generex Biotechnology (United States), Novo Nordisk (United States), Synergy Pharmaceuticals (United Arab Emirates), Tarsa Therapeutics (United States), Sanofi (France), Hoffmann-La Roche (Switzerland) and Synthetic Biologics (United States)

The Global Oral Proteins and Peptides market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

What can be explored with Oral Proteins and Peptides study:
• Where Oral Proteins and Peptides industry stands in scaling its end use implementations
• What concrete benefits would result from scaled initiatives by Players
• Where Players should focus their investments cycle
• Key success factors and recommendations for upscaling future growth.
• Target Market / Country and Key Business Segments

Available Customization:
List of players that can be included in the study on immediate basis are Hovione and Novartis.


Report Objectives / Segmentation Covered

By Type
  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin
  • Octreotide
By Application
  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders
By Distribution Channel
  • Hopsitals
  • Pharmaceuticals

By End Use
  • Hospitals
  • Physicians’ offices
  • Commercial laboratories
  • Health care centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in prevalence of chronic diseases,
      • 3.2.2. Rise in patient preference for oral drugs and enhanced patient compliance
      • 3.2.3. Surge in elderly population
    • 3.3. Market Challenges
      • 3.3.1. Low bioavailability of these drugs in the body
    • 3.4. Market Trends
      • 3.4.1. Improvement in healthcare settings
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oral Proteins and Peptides, by Type, Application, Distribution Channel, End Use and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Oral Proteins and Peptides (Value)
      • 5.2.1. Global Oral Proteins and Peptides by: Type (Value)
        • 5.2.1.1. Linaclotide
        • 5.2.1.2. Plecanatide
        • 5.2.1.3. Calcitonin
        • 5.2.1.4. Insulin
        • 5.2.1.5. Octreotide
      • 5.2.2. Global Oral Proteins and Peptides by: Application (Value)
        • 5.2.2.1. Gastric & Digestive Disorders
        • 5.2.2.2. Bone Diseases
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Hormonal Disorders
      • 5.2.3. Global Oral Proteins and Peptides by: Distribution Channel (Value)
        • 5.2.3.1. Hopsitals
        • 5.2.3.2. Pharmaceuticals
      • 5.2.4. Global Oral Proteins and Peptides by: End Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Physicians’ offices
        • 5.2.4.3. Commercial laboratories
        • 5.2.4.4. Health care centers
      • 5.2.5. Global Oral Proteins and Peptides Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Oral Proteins and Peptides (Price)
      • 5.3.1. Global Oral Proteins and Peptides by: Type (Price)
  • 6. Oral Proteins and Peptides: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biocon (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Generex Biotechnology (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Synergy Pharmaceuticals (United Arab Emirates)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Tarsa Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hoffmann-La Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Synthetic Biologics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oral Proteins and Peptides Sale, by Type, Application, Distribution Channel, End Use and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Oral Proteins and Peptides (Value)
      • 7.2.1. Global Oral Proteins and Peptides by: Type (Value)
        • 7.2.1.1. Linaclotide
        • 7.2.1.2. Plecanatide
        • 7.2.1.3. Calcitonin
        • 7.2.1.4. Insulin
        • 7.2.1.5. Octreotide
      • 7.2.2. Global Oral Proteins and Peptides by: Application (Value)
        • 7.2.2.1. Gastric & Digestive Disorders
        • 7.2.2.2. Bone Diseases
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Hormonal Disorders
      • 7.2.3. Global Oral Proteins and Peptides by: Distribution Channel (Value)
        • 7.2.3.1. Hopsitals
        • 7.2.3.2. Pharmaceuticals
      • 7.2.4. Global Oral Proteins and Peptides by: End Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Physicians’ offices
        • 7.2.4.3. Commercial laboratories
        • 7.2.4.4. Health care centers
      • 7.2.5. Global Oral Proteins and Peptides Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Oral Proteins and Peptides (Price)
      • 7.3.1. Global Oral Proteins and Peptides by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oral Proteins and Peptides: by Type(USD Million)
  • Table 2. Oral Proteins and Peptides Linaclotide , by Region USD Million (2015-2020)
  • Table 3. Oral Proteins and Peptides Plecanatide , by Region USD Million (2015-2020)
  • Table 4. Oral Proteins and Peptides Calcitonin , by Region USD Million (2015-2020)
  • Table 5. Oral Proteins and Peptides Insulin , by Region USD Million (2015-2020)
  • Table 6. Oral Proteins and Peptides Octreotide , by Region USD Million (2015-2020)
  • Table 7. Oral Proteins and Peptides: by Application(USD Million)
  • Table 8. Oral Proteins and Peptides Gastric & Digestive Disorders , by Region USD Million (2015-2020)
  • Table 9. Oral Proteins and Peptides Bone Diseases , by Region USD Million (2015-2020)
  • Table 10. Oral Proteins and Peptides Diabetes , by Region USD Million (2015-2020)
  • Table 11. Oral Proteins and Peptides Hormonal Disorders , by Region USD Million (2015-2020)
  • Table 12. Oral Proteins and Peptides: by Distribution Channel(USD Million)
  • Table 13. Oral Proteins and Peptides Hopsitals , by Region USD Million (2015-2020)
  • Table 14. Oral Proteins and Peptides Pharmaceuticals , by Region USD Million (2015-2020)
  • Table 15. Oral Proteins and Peptides: by End Use(USD Million)
  • Table 16. Oral Proteins and Peptides Hospitals , by Region USD Million (2015-2020)
  • Table 17. Oral Proteins and Peptides Physicians’ offices , by Region USD Million (2015-2020)
  • Table 18. Oral Proteins and Peptides Commercial laboratories , by Region USD Million (2015-2020)
  • Table 19. Oral Proteins and Peptides Health care centers , by Region USD Million (2015-2020)
  • Table 20. South America Oral Proteins and Peptides, by Country USD Million (2015-2020)
  • Table 21. South America Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 22. South America Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 23. South America Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 24. South America Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 25. Brazil Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 26. Brazil Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 27. Brazil Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 28. Brazil Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 29. Argentina Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 30. Argentina Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 31. Argentina Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 32. Argentina Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 33. Rest of South America Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 36. Rest of South America Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 37. Asia Pacific Oral Proteins and Peptides, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 41. Asia Pacific Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 42. China Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 43. China Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 44. China Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 45. China Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 46. Japan Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 47. Japan Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 48. Japan Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 49. Japan Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 50. India Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 51. India Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 52. India Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 53. India Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 54. South Korea Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 55. South Korea Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 56. South Korea Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 57. South Korea Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 58. Taiwan Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 59. Taiwan Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 60. Taiwan Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 61. Taiwan Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 62. Australia Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 63. Australia Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 64. Australia Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 65. Australia Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 70. Europe Oral Proteins and Peptides, by Country USD Million (2015-2020)
  • Table 71. Europe Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 72. Europe Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 73. Europe Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 74. Europe Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 75. Germany Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 76. Germany Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 77. Germany Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 78. Germany Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 79. France Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 80. France Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 81. France Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 82. France Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 83. Italy Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 84. Italy Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 85. Italy Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 86. Italy Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 87. United Kingdom Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 90. United Kingdom Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 91. Netherlands Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 92. Netherlands Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 93. Netherlands Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 94. Netherlands Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 95. Rest of Europe Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 98. Rest of Europe Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 99. MEA Oral Proteins and Peptides, by Country USD Million (2015-2020)
  • Table 100. MEA Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 101. MEA Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 102. MEA Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 103. MEA Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 104. Middle East Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 105. Middle East Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 106. Middle East Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 107. Middle East Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 108. Africa Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 109. Africa Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 110. Africa Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 111. Africa Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 112. North America Oral Proteins and Peptides, by Country USD Million (2015-2020)
  • Table 113. North America Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 114. North America Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 115. North America Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 116. North America Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 117. United States Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 118. United States Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 119. United States Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 120. United States Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 121. Canada Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 122. Canada Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 123. Canada Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 124. Canada Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 125. Mexico Oral Proteins and Peptides, by Type USD Million (2015-2020)
  • Table 126. Mexico Oral Proteins and Peptides, by Application USD Million (2015-2020)
  • Table 127. Mexico Oral Proteins and Peptides, by Distribution Channel USD Million (2015-2020)
  • Table 128. Mexico Oral Proteins and Peptides, by End Use USD Million (2015-2020)
  • Table 129. Oral Proteins and Peptides: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Oral Proteins and Peptides: by Type(USD Million)
  • Table 141. Oral Proteins and Peptides Linaclotide , by Region USD Million (2021-2026)
  • Table 142. Oral Proteins and Peptides Plecanatide , by Region USD Million (2021-2026)
  • Table 143. Oral Proteins and Peptides Calcitonin , by Region USD Million (2021-2026)
  • Table 144. Oral Proteins and Peptides Insulin , by Region USD Million (2021-2026)
  • Table 145. Oral Proteins and Peptides Octreotide , by Region USD Million (2021-2026)
  • Table 146. Oral Proteins and Peptides: by Application(USD Million)
  • Table 147. Oral Proteins and Peptides Gastric & Digestive Disorders , by Region USD Million (2021-2026)
  • Table 148. Oral Proteins and Peptides Bone Diseases , by Region USD Million (2021-2026)
  • Table 149. Oral Proteins and Peptides Diabetes , by Region USD Million (2021-2026)
  • Table 150. Oral Proteins and Peptides Hormonal Disorders , by Region USD Million (2021-2026)
  • Table 151. Oral Proteins and Peptides: by Distribution Channel(USD Million)
  • Table 152. Oral Proteins and Peptides Hopsitals , by Region USD Million (2021-2026)
  • Table 153. Oral Proteins and Peptides Pharmaceuticals , by Region USD Million (2021-2026)
  • Table 154. Oral Proteins and Peptides: by End Use(USD Million)
  • Table 155. Oral Proteins and Peptides Hospitals , by Region USD Million (2021-2026)
  • Table 156. Oral Proteins and Peptides Physicians’ offices , by Region USD Million (2021-2026)
  • Table 157. Oral Proteins and Peptides Commercial laboratories , by Region USD Million (2021-2026)
  • Table 158. Oral Proteins and Peptides Health care centers , by Region USD Million (2021-2026)
  • Table 159. South America Oral Proteins and Peptides, by Country USD Million (2021-2026)
  • Table 160. South America Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 161. South America Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 162. South America Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 163. South America Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 164. Brazil Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 165. Brazil Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 166. Brazil Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 167. Brazil Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 168. Argentina Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 169. Argentina Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 170. Argentina Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 171. Argentina Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 172. Rest of South America Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 175. Rest of South America Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 176. Asia Pacific Oral Proteins and Peptides, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 180. Asia Pacific Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 181. China Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 182. China Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 183. China Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 184. China Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 185. Japan Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 186. Japan Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 187. Japan Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 188. Japan Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 189. India Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 190. India Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 191. India Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 192. India Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 193. South Korea Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 194. South Korea Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 195. South Korea Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 196. South Korea Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 197. Taiwan Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 198. Taiwan Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 199. Taiwan Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 200. Taiwan Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 201. Australia Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 202. Australia Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 203. Australia Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 204. Australia Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 209. Europe Oral Proteins and Peptides, by Country USD Million (2021-2026)
  • Table 210. Europe Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 211. Europe Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 212. Europe Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 213. Europe Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 214. Germany Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 215. Germany Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 216. Germany Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 217. Germany Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 218. France Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 219. France Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 220. France Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 221. France Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 222. Italy Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 223. Italy Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 224. Italy Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 225. Italy Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 226. United Kingdom Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 229. United Kingdom Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 230. Netherlands Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 231. Netherlands Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 232. Netherlands Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 233. Netherlands Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 234. Rest of Europe Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 237. Rest of Europe Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 238. MEA Oral Proteins and Peptides, by Country USD Million (2021-2026)
  • Table 239. MEA Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 240. MEA Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 241. MEA Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 242. MEA Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 243. Middle East Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 244. Middle East Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 245. Middle East Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 246. Middle East Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 247. Africa Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 248. Africa Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 249. Africa Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 250. Africa Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 251. North America Oral Proteins and Peptides, by Country USD Million (2021-2026)
  • Table 252. North America Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 253. North America Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 254. North America Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 255. North America Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 256. United States Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 257. United States Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 258. United States Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 259. United States Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 260. Canada Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 261. Canada Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 262. Canada Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 263. Canada Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 264. Mexico Oral Proteins and Peptides, by Type USD Million (2021-2026)
  • Table 265. Mexico Oral Proteins and Peptides, by Application USD Million (2021-2026)
  • Table 266. Mexico Oral Proteins and Peptides, by Distribution Channel USD Million (2021-2026)
  • Table 267. Mexico Oral Proteins and Peptides, by End Use USD Million (2021-2026)
  • Table 268. Oral Proteins and Peptides: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oral Proteins and Peptides: by Type USD Million (2015-2020)
  • Figure 5. Global Oral Proteins and Peptides: by Application USD Million (2015-2020)
  • Figure 6. Global Oral Proteins and Peptides: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Oral Proteins and Peptides: by End Use USD Million (2015-2020)
  • Figure 8. South America Oral Proteins and Peptides Share (%), by Country
  • Figure 9. Asia Pacific Oral Proteins and Peptides Share (%), by Country
  • Figure 10. Europe Oral Proteins and Peptides Share (%), by Country
  • Figure 11. MEA Oral Proteins and Peptides Share (%), by Country
  • Figure 12. North America Oral Proteins and Peptides Share (%), by Country
  • Figure 13. Global Oral Proteins and Peptides: by Type USD/Units (2015-2020)
  • Figure 14. Global Oral Proteins and Peptides share by Players 2020 (%)
  • Figure 15. Global Oral Proteins and Peptides share by Players (Top 3) 2020(%)
  • Figure 16. Global Oral Proteins and Peptides share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Biocon (India) Revenue, Net Income and Gross profit
  • Figure 23. Biocon (India) Revenue: by Geography 2020
  • Figure 24. Generex Biotechnology (United States) Revenue, Net Income and Gross profit
  • Figure 25. Generex Biotechnology (United States) Revenue: by Geography 2020
  • Figure 26. Novo Nordisk (United States) Revenue, Net Income and Gross profit
  • Figure 27. Novo Nordisk (United States) Revenue: by Geography 2020
  • Figure 28. Synergy Pharmaceuticals (United Arab Emirates) Revenue, Net Income and Gross profit
  • Figure 29. Synergy Pharmaceuticals (United Arab Emirates) Revenue: by Geography 2020
  • Figure 30. Tarsa Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Tarsa Therapeutics (United States) Revenue: by Geography 2020
  • Figure 32. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi (France) Revenue: by Geography 2020
  • Figure 34. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 36. Synthetic Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 37. Synthetic Biologics (United States) Revenue: by Geography 2020
  • Figure 38. Global Oral Proteins and Peptides: by Type USD Million (2021-2026)
  • Figure 39. Global Oral Proteins and Peptides: by Application USD Million (2021-2026)
  • Figure 40. Global Oral Proteins and Peptides: by Distribution Channel USD Million (2021-2026)
  • Figure 41. Global Oral Proteins and Peptides: by End Use USD Million (2021-2026)
  • Figure 42. South America Oral Proteins and Peptides Share (%), by Country
  • Figure 43. Asia Pacific Oral Proteins and Peptides Share (%), by Country
  • Figure 44. Europe Oral Proteins and Peptides Share (%), by Country
  • Figure 45. MEA Oral Proteins and Peptides Share (%), by Country
  • Figure 46. North America Oral Proteins and Peptides Share (%), by Country
  • Figure 47. Global Oral Proteins and Peptides: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allergan (Ireland)
  • AstraZeneca (United Kingdom)
  • Biocon (India)
  • Generex Biotechnology (United States)
  • Novo Nordisk (United States)
  • Synergy Pharmaceuticals (United Arab Emirates)
  • Tarsa Therapeutics (United States)
  • Sanofi (France)
  • Hoffmann-La Roche (Switzerland)
  • Synthetic Biologics (United States)
Additional players considered in the study are as follows:
Hovione , Novartis
Select User Access Type

Key Highlights of Report


Sep 2021 241 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Oral Proteins and Peptides Quantitative research analysis
Global (United States, European Union and China) Oral Proteins and Peptides Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Oral Proteins and Peptides market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Oral Proteins and Peptides market are Allergan (Ireland), AstraZeneca (United Kingdom), Biocon (India), Generex Biotechnology (United States), Novo Nordisk (United States), Synergy Pharmaceuticals (United Arab Emirates), Tarsa Therapeutics (United States), Sanofi (France), Hoffmann-La Roche (Switzerland) and Synthetic Biologics (United States), to name a few.
"Improvement in healthcare settings" is seen as one of major influencing trends for Oral Proteins and Peptides Market during projected period 2020-2026.

Know More About Global (United States, European Union and China) Oral Proteins and Peptides Report?

Have a Query? Click Here

Other Related Reports

Platelet Rich Plasma Comprehensive Study by Type (Pure-Platelet Rich Plasma (P-PRP), Leukocyte-Platelet Rich Fibrin (L-PRF), Leukocyte-Platelet Rich Plasma (L-PRP)), Application (Orthopedics, Sports ...
$ 3650
White Biotechnology Comprehensive Study by Type (Biofuels, Biomaterials, Biochemicals, Industrial Enzymes), Application (Bioenergy, Food & Feed Additives, Pharmaceutical Ingredients, Personal Care & ...
$ 3750
Agricultural Biotechnology Comprehensive Study by Type (Genome editing tools, Deoxy ribonucleic acid (DNA) sequencing, Ribonucleic acid interference (RNAi), Synthetic biology, Biochips), Application ...
$ 3350
CD40 Ligand Comprehensive Study by Type (ISF-35, LOAd-700, MEDI-4920, MegaCD40L, Other), Application (Hepatitis B, Bladder Cancer, Liver Cancer, Ovarian Cancer, Others) Players and Region - Global Ma...
$ 3500
Pipettes Sales Comprehensive Study by Type (Volumetric Pipettes, Graduated Pipettes, Pasteur Pipettes, Others), Application (Pharmaceutical Laboratories, Biotech Laboratories, Forensics Laboratories,...
$ 3500
Immunohematology Comprehensive Study by Type (Reagents, Analyzers (Automatic and Semi-automatic/Manual)), Application (Blood-Related Diseases, HIV, Hepatitis), Technology (Microplates, Biochips, Gel ...
$ 3750